Idarubicin is one of the most recently introduced agents which has gained increasing interest andd is beginning to be widely administered both for the first and second line treatment of AML as well as in breast cancer [1, 2]. In order to provide the basis for its clinical use the pharmacokinetics of this agent have been the topic of many investigations [3–5]. This paper gives an overview of the available literature on the pharmacokinetics of idarubicin and its main metabolite idarubicinol after intravenous and oral administration and demonstrates the results from our own pharmacokinetic studies on the pharmacokinetics of idarubicin after repeated oral administration. In order to obtain an overwiew of the pharmacokinetics of idarubicin the following key determinants must be evaluated.
KeywordsToxicity HPLC Leukemia Cytosine Methoxy
Unable to display preview. Download preview PDF.
- 3.Broggini M, Sommacampagna B, Paolini A, Ersilia D, Grazia D (1986) Comparative metabolism of daunorubicin and 4-demethosydaunorubicin in mice and rabbits. Cancer Treat Rep 6: 697–702Google Scholar
- 4.Zhini G,Vicario GP, Lazzati M, Armacone F (1986) Disposition and metabolism of (14-C) 4-demethoxydaunorubicin HCL (Idarubicin) and (14-C) daunorubicin HCL in the rat. Cancer Chemother Pharmacol 16: 107–115Google Scholar
- 5.Tamassia V, Pacciarini MA, Moro E, Piazza E,Vago G, Libretti A (1987) Pharmacokinetic study of intravenous and oral Idarubicin in cancer patients. Int J Clin Pharmacol Res 5: 419–426Google Scholar
- 6.Heinzel G, Hammer R, Wolf M, Koss FW, Bozler G (1977) Modellentwicklung in der Pharmakokinetik. Drug Res 27: 904–911Google Scholar